Pzena Investment Management LLC Sells 578,950 Shares of Phibro Animal Health Corporation (NASDAQ:PAHC)

Pzena Investment Management LLC trimmed its position in shares of Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) by 44.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 723,830 shares of the company's stock after selling 578,950 shares during the quarter. Pzena Investment Management LLC owned approximately 1.79% of Phibro Animal Health worth $15,461,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Principal Financial Group Inc. lifted its holdings in shares of Phibro Animal Health by 2.6% during the first quarter. Principal Financial Group Inc. now owns 101,356 shares of the company's stock valued at $2,165,000 after purchasing an additional 2,573 shares during the last quarter. Cardinal Capital Management lifted its holdings in shares of Phibro Animal Health by 9.6% during the first quarter. Cardinal Capital Management now owns 75,010 shares of the company's stock valued at $1,602,000 after purchasing an additional 6,568 shares during the last quarter. Sowell Financial Services LLC purchased a new position in shares of Phibro Animal Health during the first quarter valued at approximately $1,977,000. Axecap Investments LLC purchased a new position in shares of Phibro Animal Health during the first quarter valued at approximately $3,696,000. Finally, Harbor Capital Advisors Inc. lifted its holdings in shares of Phibro Animal Health by 4,727.2% during the first quarter. Harbor Capital Advisors Inc. now owns 10,813 shares of the company's stock valued at $231,000 after purchasing an additional 10,589 shares during the last quarter. 99.34% of the stock is owned by institutional investors.

Phibro Animal Health Stock Performance

NASDAQ:PAHC traded down $0.32 during trading hours on Friday, reaching $29.41. The company had a trading volume of 353,025 shares, compared to its average volume of 224,464. The company has a current ratio of 2.91, a quick ratio of 1.23 and a debt-to-equity ratio of 2.67. Phibro Animal Health Corporation has a 52 week low of $16.16 and a 52 week high of $31.80. The firm has a market cap of $1.19 billion, a price-to-earnings ratio of 37.71, a PEG ratio of 0.50 and a beta of 0.75. The firm's 50 day moving average price is $25.63 and its 200-day moving average price is $22.70.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.52 by $0.11. Phibro Animal Health had a net margin of 2.68% and a return on equity of 30.51%. The business had revenue of $347.80 million during the quarter, compared to the consensus estimate of $352.41 million. On average, analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 25th. Stockholders of record on Wednesday, June 4th were given a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.63%. The ex-dividend date of this dividend was Wednesday, June 4th. Phibro Animal Health's payout ratio is 61.54%.

Analysts Set New Price Targets

Several research firms have recently issued reports on PAHC. BNP Paribas upgraded shares of Phibro Animal Health to a "hold" rating in a report on Monday, June 16th. JPMorgan Chase & Co. upgraded shares of Phibro Animal Health from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $25.00 to $35.00 in a report on Monday, July 7th. Wall Street Zen upgraded shares of Phibro Animal Health from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Morgan Stanley set a $26.00 price objective on shares of Phibro Animal Health and gave the stock an "equal weight" rating in a report on Wednesday, June 25th. Finally, BNP Paribas Exane upgraded shares of Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price objective for the company in a report on Monday, June 16th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $24.40.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.